Pennsylvania Code & Bulletin
COMMONWEALTH OF PENNSYLVANIA

• No statutes or acts will be found at this website.

The Pennsylvania Bulletin website includes the following: Rulemakings by State agencies; Proposed Rulemakings by State agencies; State agency notices; the Governor’s Proclamations and Executive Orders; Actions by the General Assembly; and Statewide and local court rules.

PA Bulletin, Doc. No. 13-2463

NOTICES

STATE HORSE RACING COMMISSION

Schedule of Therapeutic Substances

[43 Pa.B. 7612]
[Saturday, December 28, 2013]

 The State Horse Racing Commission (Commission), in accordance with the Race Horse Industry Reform Act (4 P. S. §§ 325.101—325.402), and more specifically 58 Pa. Code § 163.304 (relating to substances of therapeutic value), adopts the schedule of therapeutic medications established by the Racing Medication and Testing Consortium (RMTC) and adopted by the Association of Racing Commissioners International (ARCI).

 Under 58 Pa. Code § 163.304, the Commission may approve and adopt by reference the RMTC/ARCI schedule of therapeutic medications and their respective threshold levels. On July 11, 2013, at its public meeting the Commission formally approved the schedule set forth as follows. This schedule shall take effect on January 1, 2014. The Commission will publish any subsequent amendments or additions to the RMTC/ARCI therapeutic schedule.

 The Commission did not engage in an independent testing evaluation of the administration times or administration dosage for these medications. Individuals using the enumerated therapeutic medications are encouraged to seek the advice of their respective Veterinarians.

RMTC

Controlled Therapeutic Medications

Substance Restricted
Administration Time
Threshold Route of Administration Experimental Administration Dosage
Acepromazine 48 hours HEPS—10 ng/mL of urine Intravenous 0.05 mg/kg
Betamethasone 7 days 10 pg/mL in plasma or
serum
slntra-articular 9 mg total in one articular space
Butorphanol 48 hours Free butorphanol—
2 ng/mL of plasma, or
Total butorphanol—
300 ng/mL of urine.
Intravenous 0.1 mg/kg
Clenbuterol 14 days 140 pg/mL of urine or
LOD in plasma
Oral 0.8 mcg/kg
Dantrolene 48 hours 5-OH dantrolene—
0.1 ng/mL of plasma
or serum
Oral 500 mg total dose
Detomidine 72 hours 1 ng/mL of carboxy-
detomidine in
urine; LOD for detomidine
in plasma
Sublingual detomidine (Domosedan gel) 40 mcg/kg
Dexamethasone 72 hours 5 pg/mL of plasma or
serum
Oral, Intravenous,
IM
0.05 mg/kg
Diclofenac 48 hours 5 ng/mL of plasma or
serum
Topical 5" ribbon of Surpass every 12 hours to one site
DMSO 48 hours 10 mcg/mL of plasma or serum Oral or IV
Firocoxib 14 days 20 ng/nriL of plasma or serum Oral 0.1 mg/kg for 4 days
Flunixin 24 hours 20 ng/mL of plasma or
serum
Intravenous 1.1 mg/kg
Furosemide 4 hours 100 ng/mL in blood and
urine specific gravity
< 1.010
Intravenous Up to 500 mg total dose
Glycopyrrolate 48 hours 3 pg/mL of plasma or
serum
Intravenous1 mg total dose
Ketoprofen24 hours10 ng/mL of plasma or
serum
Intravenous2.2 mg/kg
Lidocaine (interim)72 hours20 pg/mL of total 30H-lidocaine in plasma Subcutaneous—
distal limb
200 mg of lidocaine Hydrochloride salt
Mepivacaine 72 hours 30H-mepivacaine—10 ng/mL in urine or mepivacaine at LOD in plasma Subcutaneous—
distal limb
0.07 mg/kg
Methocarbamol48 hours 1 ng/mL of plasma or
serum
IV or Oral 15 mg/kg IV, 5 g oral
Methylprednisolone 7 days 100 pg/mL in plasma or serum Intra-articular 100 mg total in one articular space *
Omeprazole24 hours omeprazole sulfide—
1 ng/mL in urine
Oral 3.9 mg/kg
Phenylbutazone 24 hours 2 mcg/mL of plasma or
serum
Intravenous 4 mg/kg
Prednisolone48 hours 1 ng/mL of plasma or serum Oral1 mg/kg
Procaine penicillinTime of entry 25 ng/mL of plasma Intra-muscular
Triamcinolone  acetonide 7 days 100 pg/mL of plasma or serum Intra-muscular9mg total in one articular space
Xylazine (interim)48 hours 0.01 ng/mL of plasma Intravenous

 * Note: At the 100 mg experimental dose, the safe time for administration to meet the 100 pg/mL threshold was 21 days—the 7 day withdrawal time anticipates that protocols vary and a smaller dose may be utilized which may allow plasma concentrations to fall below the threshold more quickly.

WALTER REMMERT, 
Acting Executive Secretary

[Pa.B. Doc. No. 13-2463. Filed for public inspection December 27, 2013, 9:00 a.m.]



No part of the information on this site may be reproduced for profit or sold for profit.

This material has been drawn directly from the official Pennsylvania Bulletin full text database. Due to the limitations of HTML or differences in display capabilities of different browsers, this version may differ slightly from the official printed version.